Ultragenyx Pharmaceutical
RARE · NASDAQ · Health Care · Pharmaceutical Preparations
Pharmaceutical Preparations company based in Novato, Ca.
Example public filing
Rep. Gilbert Cisneros (CA31) disclosed a purchase $1K–$15K
Rep. Gilbert Cisneros (CA31) disclosed a purchase of Ultragenyx Pharmaceutical in the $1K–$15K range.
- $1,001–$15,000
- Reported range · official band, not an exact amount
- 35 days
- Disclosure lag
- Traded
- Mar 3, 2026
- Disclosed
- Apr 7, 2026
Data as of Oct 11, 2026. A real record from the official source, chosen as the most recent insider trade or, failing that, the most recent filing of another kind; not a recommendation.
On file for RARE, last 12 months
- 0
- Insider filings
- 2
- Congress trades
- 23
- Fund positions
- 0
- Federal contracts
Records OQRO holds, counted by their date; a 13F position is counted once per quarter it is reported.
Insider buying and selling since 2014
Insiders of Ultragenyx Pharmaceutical reported 8 open-market purchases and 303 sales since 2014; purchases in 3 different years, most recently 2019.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | 17×17 trades |
| 2024 | — | 22×22 trades |
| 2023 | — | 21×21 trades |
| 2022 | — | 18×18 trades |
| 2021 | — | 42×42 trades |
| 2020 | — | 50×50 trades |
| 2019 | 1×1 trade | 11×11 trades |
| 2018 | — | 14×14 trades |
| 2017 | 2×2 trades | 4×4 trades |
| 2016 | — | 37×37 trades |
| 2015 | — | 53×53 trades |
| 2014 | 5×5 trades | 14×14 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. The amounts, the people and every filing are in OQRO Pro.
See the full picture with OQRO Pro.
25 records for Ultragenyx Pharmaceutical in the last 12 months, each linked to its filing. Full histories, the screener, alerts for the companies you follow and Ask OQRO.
Latest disclosures
Secure payment by Stripe. Renews every month until you cancel; cancel anytime from your account. No free trial.
Public previews are free. Full research requires Pro. No free trial.
What this page holds
- Insider trades and planned sales
- Politician trades (House and Senate)
- Fund holdings from 13F filings
- Federal contracts, lobbying and short selling
- Full history and context, with a link to every filing
What OQRO is
OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.
Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.
Questions about Ultragenyx Pharmaceutical insider trading
Have Ultragenyx Pharmaceutical insiders bought shares recently?
No open-market purchase by an insider of Ultragenyx Pharmaceutical was filed in the last 90 days. The latest on record was on Sep 11, 2019.
How often do Ultragenyx Pharmaceutical insiders buy and sell shares?
Since 2014, Ultragenyx Pharmaceutical insiders reported 8 open-market purchases and 303 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2019.
Do members of Congress trade RARE?
Yes. Members of Congress disclosed 2 trades in Ultragenyx Pharmaceutical (RARE) in the last 12 months, each reported as a value range on a periodic transaction report.
When does Ultragenyx Pharmaceutical report its next results?
Ultragenyx Pharmaceutical's next results are expected on Nov 4, 2026. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.